Processing

Please wait...

Settings

Settings

Goto Application

1. WO2016138199 - BENZOTHIAZOLE AND BENZOTHIOPHNE COMPOUNDS

Publication Number WO/2016/138199
Publication Date 01.09.2016
International Application No. PCT/US2016/019453
International Filing Date 25.02.2016
IPC
C07D 513/04 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
513Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/, C07D477/232
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
A61K 31/433 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
433Thiadiazoles
A61P 7/02 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
7Drugs for disorders of the blood or the extracellular fluid
02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
CPC
A61K 31/426
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
425Thiazoles
4261,3-Thiazoles
A61K 31/495
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
A61P 7/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
7Drugs for disorders of the blood or the extracellular fluid
02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
C07D 513/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
513Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
Applicants
  • BRISTOL-MYERS SQUIBB COMPANY [US]/[US]
  • UNIVERSITE DE MONTREAL [CA]/[CA]
Inventors
  • RUEDIGER, Edward, H.
  • DEON, Daniel, H.
  • GAGNON, Marc
  • POSY, Shoshana, L.
Agents
  • KALYANARAMAN, Palaiur
Priority Data
62/120,98826.02.2015US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) BENZOTHIAZOLE AND BENZOTHIOPHNE COMPOUNDS
(FR) COMPOSÉS BENZOTHIOPHÈNE ET BENZOTHIAZOLE
Abstract
(EN)
The present invention provides benzothiazole compounds or benzothiophene compounds of Formula I having the structure: wherein X1, X2, X3, X4, X5, Y, WR2,R3, R4, R5, R6, R7 and AA and other moieties are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
(FR)
La présente invention concerne des composés benzothiazole ou des composés benzothiophène de formule I ayant pour structure : dans laquelle X1, X2, X3, X4, X5, Y, WR2, R3, R4, R5, R6, R7 et AA ainsi que d'autres motifs sont tels que définis dans la présente invention, ou un stéréo-isomère, un tautomère, un sel pharmaceutiquement acceptable, un ester de promédicament ou sa forme solvate. Ces composés sont des inhibiteurs de l'agrégation plaquettaire et peuvent ainsi être utilisés comme médicaments pour le traitement ou la prévention de troubles thromboemboliques.
Also published as
Latest bibliographic data on file with the International Bureau